Further study of the five quite novel proteins, including ACTBL2 (Q562R1), MBL2 (P11226), BPI (P17213), EIF3D (O15371) and CR1 (P17927), which are potential therapeutic targets and candidate biomarkers for IBD patients with IFX non-response, and pathways identified in the present study should allow a better understanding of the molecular mechanisms of infliximab action and mechanisms of resistance to anti-TNF therapy. The gene discussed is CR1; the disease is inflammatory bowel disease.